Improving

Human Health

We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.

Continuing to

Grow & Invest

We are an evergreen fund that has a long-term investment perspective.

Focusing on the

Mid-Atlantic Region

We invest in life-science companies in the Mid-Atlantic region.

Launching Successful

Companies

Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.

Latest News

Multicenter, Prospective, Observational, Implementation Science Study Demonstrates Value of Infrascanner in TBI Triage During Large Scale Combat Operations

Multicenter, Prospective, Observational, Implementation Science Study Demonstrates Value of Infrascanner in TBI Triage During Large Scale Combat Operations

Tolerance Bio Licenses Clinical-Stage Anti-IL-33 Monoclonal Antibody from Tanabe Pharma to Expand Thymus-Focused Clinical Pipeline

Tolerance Bio Licenses Clinical-Stage Anti-IL-33 Monoclonal Antibody from Tanabe Pharma to Expand Thymus-Focused Clinical Pipeline

AMA and Atalan Launch Collaboration to Advance Physician Retention Research

AMA and Atalan Launch Collaboration to Advance Physician Retention Research

ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors

ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors

VIEW MORE NEWS
Learn more

Who We Are

OUR COMPANY
Learn more

Who We Support

OUR PORTFOLIO